May 30 |
Carisma Therapeutics to Participate in the Jefferies Global Healthcare Conference
|
May 16 |
Carisma Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of CT-0525, a Novel HER2-Targeting CAR-Monocyte
|
May 14 |
Is There An Opportunity With Carisma Therapeutics, Inc.'s (NASDAQ:CARM) 46% Undervaluation?
|
May 9 |
Carisma Therapeutics Inc. (CARM) Reports Q1 Loss, Misses Revenue Estimates
|
May 9 |
Carisma Therapeutics GAAP EPS of -$0.46 misses by $0.03, revenue of $3.39M misses by $1.01M
|
May 9 |
Carisma Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
|
May 8 |
Carisma Therapeutics Presents Preclinical Proof of Concept Data Demonstrating the Anti-Fibrotic Potential of Engineered Macrophages at ASGCT 2024
|
May 6 |
Carisma Therapeutics to Participate in The Citizens JMP Life Sciences Conference
|
May 2 |
Carisma Therapeutics Inc. (CARM) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
|
May 2 |
Carisma Therapeutics names Eugene Kennedy as chief medical officer
|